Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case–control study

[1]  Te-Wei Ho,et al.  Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease , 2019, Respiratory Research.

[2]  Y. Oh,et al.  Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts , 2019, Respiratory Research.

[3]  D. Lauro,et al.  Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD , 2018, Current opinion in pharmacology.

[4]  Y. Kuo,et al.  Metformin use and health care utilization in patients with coexisting chronic obstructive pulmonary disease and diabetes mellitus , 2018, International journal of chronic obstructive pulmonary disease.

[5]  Jin Hwa Kim,et al.  Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus , 2017, The Korean journal of internal medicine.

[6]  M. Cazzola,et al.  Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. , 2017, Trends in pharmacological sciences.

[7]  Te-Wei Ho,et al.  Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality , 2017, PloS one.

[8]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report , 2017, Respirology.

[9]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary , 2017, European Respiratory Journal.

[10]  P. Proost,et al.  Regulation of Chemokine Activity – A Focus on the Role of Dipeptidyl Peptidase IV/CD26 , 2016, Frontiers in immunology.

[11]  H. Chiou,et al.  Risk of arteriovenous fistula failure associated with hypnotic use in hemodialysis patients: a nested case‐control study , 2016, Pharmacoepidemiology and drug safety.

[12]  John A. Galdo,et al.  Hypoglycemic agents and potential anti-inflammatory activity , 2016, Journal of inflammation research.

[13]  Hongyan Ni,et al.  NLRP3 inflammasome is essential for the development of chronic obstructive pulmonary disease. , 2015, International journal of clinical and experimental pathology.

[14]  Chuan-Fen Liu,et al.  Thiazolidinediones are associated with a reduced risk of COPD exacerbations , 2015, International journal of chronic obstructive pulmonary disease.

[15]  N. Scichilone,et al.  Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. , 2015, Pulmonary pharmacology & therapeutics.

[16]  J. Roca,et al.  Network medicine analysis of COPD multimorbidities , 2014, Respiratory Research.

[17]  W. Yao,et al.  Time course of inflammation resolution in patients with frequent exacerbations of chronic obstructive pulmonary disease , 2014, Medical science monitor : international medical journal of experimental and clinical research.

[18]  A. Consoli,et al.  Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? , 2013, Diabetes, obesity & metabolism.

[19]  P. Kirkham,et al.  Oxidative stress in COPD. , 2013, Chest.

[20]  D. Sin,et al.  Lung inflammation in COPD: why does it matter? , 2012, F1000 medicine reports.

[21]  A. Mirrakhimov.  Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony , 2012, Cardiovascular Diabetology.

[22]  Claudio Pedone,et al.  Comorbidities of chronic obstructive pulmonary disease , 2011, Current opinion in pulmonary medicine.

[23]  J. Rains,et al.  Oxidative stress, insulin signaling, and diabetes. , 2011, Free radical biology & medicine.

[24]  B. Make,et al.  Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data , 2011, BMC health services research.

[25]  E. Ravussin,et al.  The NALP3/NLRP3 Inflammasome Instigates Obesity-Induced Autoinflammation and Insulin Resistance , 2010, Nature Medicine.

[26]  D. Suh,et al.  Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. , 2010, Journal of diabetes and its complications.

[27]  S. Suissa,et al.  Inhaled corticosteroids and the risks of diabetes onset and progression. , 2010, The American journal of medicine.

[28]  G. Marks,et al.  Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD , 2010, Respirology.

[29]  C. Glass,et al.  Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells , 2010, Nature Reviews Immunology.

[30]  E. Roughead,et al.  Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. , 2010, Diabetes research and clinical practice.

[31]  W. Kuschner,et al.  The Effect of an Inhaled Corticosteroid on Glucose Control in Type 2 Diabetes , 2009, Clinical Medicine Research.

[32]  D. Au,et al.  The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. , 2009, The American journal of medicine.

[33]  A. Barnett.  Redefining the role of thiazolidinediones in the management of type 2 diabetes , 2009, Vascular health and risk management.

[34]  G. Gensini,et al.  Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials , 2008, Diabetes, obesity & metabolism.

[35]  Renee F Wilson,et al.  Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. , 2008, Archives of internal medicine.

[36]  John D. Piette,et al.  Beyond Comorbidity Counts: How Do Comorbidity Type and Severity Influence Diabetes Patients’ Treatment Priorities and Self-Management? , 2007, Journal of General Internal Medicine.

[37]  G. Donaldson,et al.  Inflammatory changes, recovery and recurrence at COPD exacerbation , 2007, European Respiratory Journal.

[38]  T. Seemungal,et al.  Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD , 2005, Chest.

[39]  P. Di Meglio,et al.  Mechanism of the Anti-Inflammatory Effect of Thiazolidinediones: Relationship with the Glucocorticoid Pathway , 2005, Molecular Pharmacology.

[40]  A. Sugawara,et al.  Transcriptional Suppression of Type 1 Angiotensin II Receptor Gene Expression by Peroxisome Proliferator-Activated Receptor-γ in Vascular Smooth Muscle Cells. , 2001, Endocrinology.

[41]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[42]  T. Seemungal,et al.  Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels , 2000, Thrombosis and Haemostasis.

[43]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[44]  T. Seemungal,et al.  Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations , 2000, Thorax.

[45]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[46]  W. Kern,et al.  Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. , 1997, The Journal of allergy and clinical immunology.

[47]  D. Skowasch,et al.  [Comorbidities in Chronic Obstructive Pulmonary Disease]. , 2019, Deutsche medizinische Wochenschrift.

[48]  M. Korytkowski.  Section 9: Pharmacologic Approaches to Glycemic Treatment , 2024, Clinical diabetes : a publication of the American Diabetes Association.

[49]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[50]  A. Sugawara,et al.  Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. , 2001, Endocrinology.

[51]  W. Hsueh,et al.  Expression and function of PPARgamma in rat and human vascular smooth muscle cells. , 2000, Circulation.

[52]  L. Frith,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. , 1998, Lancet.

[53]  Rede fi ning the role of thiazolidinediones in the management of type 2 diabetes , 2022 .